Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

ORIC Pharmaceuticals Reports 84% Response Rate for Enozertinib in EGFR-Mutant NSCLC

ORIC Pharmaceuticals announced updated Phase 1b clinical data for enozertinib at the ESMO Congress 2026, demonstrating an 84% confirmed systemic objective response rate in patients with EGFR-mutant non-small cell lung cancer. The results highlight significant intracranial activity and deep molecular responses, supporting the company's plan to initiate a registrational Phase 3 trial in the first half of 2027.

Engineer, engineering, robotics, mechanical. Stock photo illustrating ORIC Pharmaceuticals' other story.
Oric Pharmaceuticals, Inc. · Healthcare · Photo: This_is_Engineering / Pixabay

Key highlights

  • Confirmed systemic objective response rate of 84% by investigator assessment and 80% by BICR
  • Deep molecular response achieved with 100% of patients reaching 90% ctDNA reduction by Cycle 3
  • Clinical data confirms efficacy across PACC mutations and L861Q variants with no new CNS lesions
  • Global Phase 3 registrational trial for enozertinib scheduled to begin in the first half of 2027
  • Safety profile showed predominantly Grade 1 or 2 events with no treatment discontinuations due to toxicities

Clinical Data Presentation

During the ESMO Congress 2026, ORIC Pharmaceuticals presented updated results from its Phase 1b trial of enozertinib, an oral EGFR inhibitor. The study focused on patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR atypical and exon 20 insertion mutations. Of the 26 patients treated with an 80 mg daily dose, the investigator-assessed confirmed systemic objective response rate reached 84%. Notably, 65% of the enrolled population had brain metastases at baseline, a rate significantly higher than observed in competitor datasets. The drug demonstrated meaningful intracranial activity and was well-tolerated, with most treatment-related adverse events resolving through dose modifications rather than permanent discontinuations.

Pipeline and Strategic Progress

  • Initiation of a global Phase 3 registrational trial for enozertinib is planned for the first half of 2027
  • Full ctDNA clearance was achieved by 82% of patients, a metric associated with improved long-term survival in prior lung cancer trials
  • Recent clinical development agreement with Cancer Research UK to advance ORIC-259 into Phase 1/2 trials as of October 2026
  • Ongoing Himalayas-1 Phase 3 study for rinzimetostat bolstered by a supply collaboration with Bayer
  • Development strategy remains focused on addressing diverse PACC and L861Q mutations that lack standard-of-care treatments

Business and Industry Landscape

ORIC Pharmaceuticals operates as a clinical-stage biotechnology company centered on overcoming resistance mechanisms in cancer therapy. The firm competes in a specialized oncology segment targeting specific epidermal growth factor receptor mutations. Its clinical pipeline, including enozertinib and rinzimetostat, aims to provide high-potency alternatives to existing inhibitors while maintaining blood-brain barrier penetration. Industry trends show a shift toward precision medicine where molecular response clearance, such as the 100% MR90 rate achieved in this trial, serves as a critical early indicator of long-term efficacy. The company’s focus on PACC mutations positions it to address a distinct subset of the non-small cell lung cancer market.

Financial Context

The company maintains a solid liquidity position to fund its transition into late-stage clinical development. According to financial updates from August 2026, ORIC holds approximately $387.6 million in cash and investments, which is projected to sustain operations into the second half of 2028. This runway follows a $125 million private placement financing completed in mid-2025. While the company does not currently generate revenue from commercial product sales, its market capitalization of $1.41 billion reflects significant investor interest in its pipeline milestones. The stock has demonstrated a 25.85% price increase over the last quarter, reflecting positive sentiment ahead of these registrational trial plans.

Oric Pharmaceuticals, Inc. share price · last month
Line chart of Oric Pharmaceuticals, Inc.'s share price over the last month, from $12.72 on 19 Oct → $7.52 on 16 Nov; our story on 23 Oct at $13.63.

Down 44.8% since our story on 23 Oct: $13.63 when we broke it → $7.52 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$12.72
20 Oct$13.78
21 Oct$13.85
22 Oct$13.63
23 Oct$13.17
26 Oct$8.96
27 Oct$9.00
28 Oct$9.30
29 Oct$8.99
30 Oct$9.24
2 Nov$9.07
3 Nov$9.59
4 Nov$9.34
5 Nov$8.49
6 Nov$8.82
9 Nov$9.23
10 Nov$8.91
11 Nov$9.00
12 Nov$8.50
13 Nov$7.86
16 Nov$7.52
Earlier announcements by Oric Pharmaceuticals, Inc.
DateAnnouncementAmount
05 Oct 2026Clinical development agreement with Cancer Research UK to advance ORIC-259 into Phase 1/2 trialsSource: biospace.com–
03 Aug 2026Second quarter 2026 financial results and operational updatesSource: investors.oricpharma.com–
14 Jul 2026Initiation of Himalayas-1 Phase 3 trial and darolutamide supply collaboration with BayerSource: investors.oricpharma.com–
31 Mar 2026Selection of rinzimetostat recommended Phase 3 dose for Himalayas-1 studySource: investors.oricpharma.com–
12 Aug 2025Strategic pipeline reprioritization and 20% workforce reductionSource: investors.oricpharma.com–
28 May 2025Agreement for private placement financing of common stock and pre-funded warrantsSource: investors.oricpharma.com$125.0 Million
Oric Pharmaceuticals, Inc. · financial snapshot
Share price$13.63
Market cap$1.4B
1-month price change+0.96%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by ORIC Pharmaceuticals, Inc. announcing updated Phase 1b clinical data for enozertinib at the ESMO Congress 2026.

Read the filing ↗

Track Oric Pharmaceuticals, Inc. live

Get the next Oric Pharmaceuticals, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.